techcentury.com
Esperion sees positive results from final study on cholesterol-buster
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical developer, announced positive results from the final Phase 3 test of its lead drug candidate, bempedo…